Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial

In its latest gambit to preserve market share in spinal muscular atrophy, Biogen's launching a new Spinraza trial designed to determine whether a higher dose might be more effective than the one already FDA-approved.